A molecular screening approach to identify and characterize inhibitors of glioblastoma stem cells.
Koppany Visnyei, Hideyuki Onodera, Robert Damoiseaux, Kuniyasu Saigusa, Syuzanna Petrosyan, David De Vries, Denise Ferrari, Jonathan Saxe, Eduard H Panosyan, Michael Masterman-Smith, Jack Mottahedeh, Kenneth A Bradley, Jing Huang, Chiara Sabatti, Ichiro Nakano, Harley I Kornblum
文献索引:Mol. Cancer Ther. 10(10) , 1818-28, (2011)
全文:HTML全文
摘要
Glioblastoma (GBM) is among the most lethal of all cancers. GBM consist of a heterogeneous population of tumor cells among which a tumor-initiating and treatment-resistant subpopulation, here termed GBM stem cells, have been identified as primary therapeutic targets. Here, we describe a high-throughput small molecule screening approach that enables the identification and characterization of chemical compounds that are effective against GBM stem cells. The paradigm uses a tissue culture model to enrich for GBM stem cells derived from human GBM resections and combines a phenotype-based screen with gene target-specific screens for compound identification. We used 31,624 small molecules from 7 chemical libraries that we characterized and ranked based on their effect on a panel of GBM stem cell-enriched cultures and their effect on the expression of a module of genes whose expression negatively correlates with clinical outcome: MELK, ASPM, TOP2A, and FOXM1b. Of the 11 compounds meeting criteria for exerting differential effects across cell types used, 4 compounds showed selectivity by inhibiting multiple GBM stem cells-enriched cultures compared with nonenriched cultures: emetine, n-arachidonoyl dopamine, n-oleoyldopamine (OLDA), and n-palmitoyl dopamine. ChemBridge compounds #5560509 and #5256360 inhibited the expression of the 4 mitotic module genes. OLDA, emetine, and compounds #5560509 and #5256360 were chosen for more detailed study and inhibited GBM stem cells in self-renewal assays in vitro and in a xenograft model in vivo. These studies show that our screening strategy provides potential candidates and a blueprint for lead compound identification in larger scale screens or screens involving other cancer types.
相关化合物
相关文献:
2015-01-01
[Sci. Rep. 5 , 16616, (2015)]
2009-11-01
[J. Neurochem. 111(4) , 1051-61, (2009)]
2010-01-01
[J. Biol. Chem. 285(1) , 608-19, (2010)]
2009-12-01
[Mol. Cell. Biol. 29(24) , 6380-90, (2009)]
2010-01-01
[Mol. Reprod. Dev. 77(1) , 83-91, (2010)]